HR 4030 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Treatment Continuity Act of 2025
To amend the Public Health Service Act to authorize the Secretary of Health and Human Services to address priority substance use disorder and serious mental illness treatment needs through long-acting injectable medications, and for other purposes.
Summary
This bill amends the Public Health Service Act to authorize the Secretary of Health and Human Services to use grants to address substance use disorder and serious mental illness through long-acting injectable medications approved by the FDA. The amendments expand the program to support access to these medications, lab testing, counseling, and training for healthcare providers on administering long-acting injectable medications for both conditions. The bill requires the Secretary to submit annual reports to Congress on program outcomes and treatment progress based on clinician assessments. These changes apply to grants awarded after the bill is enacted.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Rep. Dunn, Neal P. [R-FL-2] (R-FL)
3 cosponsors
Money behind the sponsor
Top reported contributors to Neal P. Dunn’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- KEDRICK CERRY $13,200
- ADVANCED UROLOGY INSTITUTE $12,400
- APPLIED RESEARCH ASSOCIATES $11,600
- NULL $11,110
- AUDIENTIS LLC $10,000
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Neal P. Dunn → · Outside spending →
Actions (2)
- Jun 17, 2025 Referred to the House Committee on Energy and Commerce. · house
- Jun 17, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
June 17, 2025
Mr. Dunn of Florida (for himself, Mr. Soto, and Mr. Bean of Florida) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend the Public Health Service Act to authorize the Secretary of Health and Human Services to address priority substance use disorder and serious mental illness treatment needs through long-acting injectable medications, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Treatment Continuity Act of 2025”.
SEC. 2. PRIORITY SUBSTANCE USE DISORDER AND SERIOUS MENTAL ILLNESS TREATMENT NEEDS OF REGIONAL AND NATIONAL SIGNIFICANCE.
(a) In General.—Section 509 of the Public Health Service Act (42 U.S.C. 290bb-2) is amended—
(1) in the section heading, by inserting “and serious mental illness” after “substance use disorder”;
(2) in subsection (a)—
(A) in the matter preceding paragraph (1), by inserting “and serious mental illness” after “substance use disorder”; and
(B) by striking paragraphs (1) through (3) and inserting the following: “
“(1) access to long-acting injectable medications that are approved by the Food and Drug Administration for the treatment of individuals with substance use disorders or serious mental illness;
“(2) lab testing and supportive counseling for substance use disorder and serious mental illness; and
“(3) training on the use of long-acting injectable medications for the purposes described in paragraph (1), in combination with associated clinical services such as counseling.”;
(3) in subsection (b)—
(A) in the subsection heading, by inserting “and Serious Mental Illness” after “Substance Use Disorder”; and
(B) in paragraphs (1) and (2), by inserting “and serious mental illness” after “substance use disorder”;
(4) by striking subsections (d) and (e) and inserting the following:
“(d) Annual Report to Congress.—Not later than 1 year after the date of enactment of the Treatment Continuity Act of 2025, and annually thereafter during the term of the program under this section, the Secretary shall transmit to Congress a report on the outcomes of such program, including completed or substantial progress toward treatment requirements based on clinician assessment.”; and
(5) by redesignating subsection (f) as subsection (e).
(b) Applicability.—The amendments made by this section shall apply to grants made under section 509 of the Public Health Service Act after the date of the enactment of this Act. <all>
Comments